Can we harness our immune system to fight NSCLC? When Maureen O'Grady was diagnosed with stage 4 lung cancer in 2009, doctors at her local hospital told her she had 12-14 Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and
Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, discusses updated results from Scott N. Gettinger, MD Medical Oncology | Yale New Haven Hospital
Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. MK-3475 (Inhibitor of PD-1) and its Efficacy in Lung Cancer Alan Sandler, MD, division chief of Hematology and Medical Oncology at Oregon Health & Science University, explains that many
Dr. Gettinger on Lung Cancer Immunotherapies | OncLive At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the
Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of Progress and Hope: Sharing the Latest Advances in Lung Cancer Care
Scott Gettinger | Specialists | Yale Medicine Nancy Sergent had Gastric Bypass surgery which ended up causing damage to the nerves of her hands and feet. She talks about
Dr. Scott Gettinger is a medical oncologist, Professor of Internal Medicine, and Chief of Thoracic Medical Oncology at the Yale School of Medicine and Smilow Roy S. Herbst, MD, PhD, Yale School of Medicine, New Haven, CT, discusses the issue of immuno-oncology (IO) resistance in Dr. Kelly on the JAVELIN Solid Tumor Trial
Immune checkpoint inhibitors and biomarker-driven strategies for managing lung cancer Primo Neary Lara Jr., MD, associate director, Translational Research, co-leader, Cancer Therapeutics Program, UC Davis
LUNG CANCER-4 (Summary) with a MCQ Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs
🎧 Lung Cancer PodCast -2 (Treatment) Overcoming immuno-oncology resistance in lung cancer
Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.Interview conducted at Nancy Sergent on Dr. Ungar
Dr. Primo Lara Discusses Emerging Therapies in Kidney Cancer Long-Term Outcomes With PD-1 Monotherapy in NSCLC
NanoString Treatment for Kidney Cancer Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital
Jeff Infante, M.D., Director of Drug Development Unit at the Sarah Cannon Research Institute discusses breakthroughs in PD1 LUNG CANCER-1 Dr RR Baliga's MUST KNOW FACTS PodCasts for Physicians from Baliga's Textbook of Internal Medicine with
In this segment, Primo N. Lara, Jr, MD; Benjamin P. Levy, MD; and Jyoti D. Patel, MD, discuss the importance of discussing The Behind the Science video series, hosted by Dr. Eric Haura, Director of the Lung Cancer Center of Excellence, takes you into Naiyer A. Rizvi, MD, associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1
LUNG CANCER-2 Dr RR Baliga's MUST KNOW FACTS PodCasts for Physicians from Baliga's Textbook of Internal Medicine with Visit for more. Dr Bollard talks to ecancertv at ASH 2014 about key abstracts highlighted by the conference In this segment, panelists discuss the exploration of PD-1 and PD-L1 inhibitors across a variety of settings for patients with
November 2, 2022 Hosted by: Sarah Goldberg, MD, MPH, and Daniel Boffa, MD Presentations on: The Latest on Lung Cancer Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors
The Promise of PD1 Inhibitors in Kidney Cancer Scott Gettinger, MD, is a medical oncologist who specializes in lung cancer treatment and research. He says the best part of his job is the ability to Jason Luke, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses the combination approach of
November 13, 2024 5:30pm – Welcome Sarah Goldberg, MD, MPH, & Justin Blasberg, MD, MPH, FACS 5:40pm – Spotlight on Advances in immunotherapy for lung cancer PD1 Inhibitors & Immunotherapy in Cancer Care
Dr. Alan Sandler Discusses Immunotherapies to Treat Lung Cancer Diwakar Davar, MBBS, MSc, assistant professor of medicine and medical oncologist/hematologist at UPMC Hillman Cancer
Dr. Sarah Goldberg from Yale Cancer Center talks about HER 2 mutation testing, filmed at IASLC in February 2014. Oncology. Discussing Maintenance Therapy with Patients
Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic
Dr. Kim, Medical Oncologists, Levine Cancer Institute, explains how anti-PD-L1/PD-1 therapies are being combined with SCOTT GETTINGER, MD (left), is a physician in medical oncology at Smilow Cancer Hospital, where he took care of Melissa and got to know the
Dr. Edward Garon from the David Geffen School of Medicine talks about MK-3475, filmed at IASLC in February 2014. Oncology. Earn CME for related activities: Drs. John M. Kirkwood and Antoni Ribas chaired the Perspectives in Dr. Rizvi on PD-1 and PD-L1 Inhibitors in Lung Cancer
Dr. Gettinger is internationally recognized for his expertise in lung cancer treatment and research. He is best known for his work in immunotherapy. 🎧 Lung Cancer PodCast -2 This lecture, by Dr. Nadia Rosenthal, discusses the role of stem cells in the regeneration and repair of tissues, and their possible
What is PD1 and PDL1 in Kidney Cancer? CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
The basic biology of PD-1/PD-L1 Scott Gettinger, MD, is Professor of Internal Medicine and Chief of Thoracic Medical Oncology. Internationally recognized for his for work in immunotherapy.
Scott Gettinger, MD | Authors | OncLive Combining CTLA-4 Agents With PD-1/PD-L1 Agents in Lung Cancer
Can Vaccines Fight Lung Cancer? "Dr. Gettinger is my primary oncologist. He IS one-in-a-million!!!! I
Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medicaloncology at Smilow Cancer This webcast from the 19th Annual Meeting of the Network of Oncology Clinicians and Researchers (NOCR) features Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer
🎧 Lung Cancer PodCast -1 SCOTT N GETTINGER, MD, Medical Oncology NEW HAVEN, CT VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with
Scott Gettinger, MD | Yale School of Medicine Dr. Scott Gettinger, MD - Medical Oncologist in New Haven, CT Scott Gettinger, MD, is a medical oncologist who specializes in lung cancer treatment and research.
Dr. Herbst on PD-1 Inhibitors in Lung Cancer UCLA's Dr. Garon Discusses PD1 and PD-L1 Drugs Treating Non-Small Cell Lung Cancer
Dr. Cheson Comments on the Potential of Anti-PD1 Agents Speakers Roy S. Herbst, MD, PhD Sarah Goldberg, MD, MPH Justin D. Blasberg, MD, MPH, FACS Katerina Politi, PhD Frederick Dr. Gettinger on the Evolution of Immunotherapies in Lung Cancer
Dr. Luke Discusses PD-1 Plus IDO Inhibitors in Melanoma Experts comment on long-term survival outcomes of CheckMate 017, CheckMate 057, and KEYNOTE-024 and optimal duration of Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi
Karen Kelly, MD, associate Director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Stem Cells and the End of Aging Part 3 of 6 NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine
Q & A with Dr. Gettinger | Yale New Haven Hospital PD-1 Inhibition in Lung Cancer Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in
David R. Gandara, MD, director, Thoracic Oncology Program, and professor, UC Davis Comprehensive Cancer Center, discusses LUNG CANCER-3 (Treatment) Dr RR Baliga's MUST KNOW FACTS PodCasts for Physicians from Baliga's Textbook of Internal
JCCC physician-scientist Edward Garon, M.D., discusses the JCCC's leadership in identifying HER 2 Mutation Testing in Lung Cancer PD-1 Checkpoint Inhibition Impacts Treatment of Melanoma and Lung Cancer
NPI Profile for SCOTT N GETTINGER in NEW HAVEN, CT. An internist who specializes in the diagnosis and treatment of all types of cancer and other benign and Behind the Science -Episode 3, Immunotherapy
Dr. Scott Gettinger, MD is a medical oncologist in New Haven, CT and has over 25 years of experience in the medical field. He graduated from State University of LUNG CANCER-4 -Summary Dr RR Baliga's MUST KNOW FACTS PodCasts for Physicians from Baliga's Textbook of Internal
Anti-PD-1/PD-L1 antibodies in lung cancer - Video abstract [ID 55176] Dr. Edward Garon, M.D., of UCLA's Jonsson Comprehensive Cancer Center is involved in clinical trials testing new cancer drugs
Getting a Second Chance with Stage 4 Lung Cancer: Maureen's Immunotherapy Story Dr. Corey Langer chairs this 18th Annual "Perspectives in Thoracic Oncology" meeting which is captured in its entirety in this Immunotherapy and NSCLC - Dr. Scott Gettinger
Dr. Scott Gettinger on the PD-1 Inhibitor BMS-936558 in Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors Explored Across NSCLC Settings
Dr. Edward Garon—Connecting for Lung Cancer Cures Will Combining Immunotherapies Better Fight Kidney Cancer?
Understanding Lung Cancer: A Conference for Patients and Families Dr. Herbst on Targeting PD-1 and PD-L1 in Lung Cancer Scott Gettinger, MD |
Experts discuss the development of immune checkpoint inhibitors as treatments for patients with non-small cell lung cancer, Lung Cancer Awareness Month Patient Event Video abstract of review paper "Targeting PD-1/PD-L1 in lung cancer: current perspectives" published in the open access Lung
Dr. Armand on PD-1 Inhibitors for Hematologic Malignancies Advances in the Management of Iodine Refractory Thyroid Cancers- Dr. Marcia Brose